Advances in incretin-based therapeutics for obesity
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Advances in incretin-based therapeutics for obesity. / Rosenkilde, Mette M.
I: Nature Reviews Endocrinology, Bind 20, 2024, s. 67–68.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Advances in incretin-based therapeutics for obesity
AU - Rosenkilde, Mette M.
PY - 2024
Y1 - 2024
N2 - The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.
AB - The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.
U2 - 10.1038/s41574-023-00938-w
DO - 10.1038/s41574-023-00938-w
M3 - Journal article
C2 - 38062121
AN - SCOPUS:85179364905
VL - 20
SP - 67
EP - 68
JO - Nature reviews. Endocrinology
JF - Nature reviews. Endocrinology
SN - 1759-5029
ER -
ID: 377451023